Individuals who suff er traumatic intracranial hemorrhages (ICHs), the most common cause of morbidity and mortality in adults younger than 40 years of age, not only incur neurologic defi cits but also are at increased risk for complications. Th warting such complications is paramount to preserving quality of life and improving the likeli hood for survival. As such, preventing venous thrombo embolism (VTE), the single most preventable cause of morbidity and mortality in neurosurgical patients, is of utmost priority. Th e decision to initiate VTE prophylaxis in the setting of a traumatic ICH must be carefully considered. Failure to use VTE prophylaxis may result in serious or fatal pulmonary embolism (PE), whereas the use of anticoagulants may potentiate further intracranial bleeding, thereby worsening neurologic function and possibly precipitating death. Th e paucity of clinical trials addressing the safety and effi cacy of chemical thromboprophylaxis in this patient population leaves clinicians guessing in regard to the appropriate dose, timing, and duration for thromboprophylaxis in the presence of an ICH. Th us, it is left to the physician at the bedside to weigh the risks versus benefi ts of anticoagulation in the face of the existing potential for a serious PE or the progression of a head bleed. Th e pivotal question is: how much preventive benefi t must be provided in order to outweigh the potential bleeding risk?
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In the previous issue of Critical Care, Scales and colleagues [1] attempted to address this question and illustrate the diffi culty of making this choice in traumatic ICH patients, particularly within 24 hours of the injury. In a decision analysis examining the risks of ICH progression versus the risks of VTE, the authors concluded that there was no clear benefi t to providing (expected value = 0.89) or withholding (expected value = 0.90) thromboprophy laxis with low-molecular-weight heparin (LMWH). Although their results were incon clusive, they erred on the side of caution and recom mended withholding anticoagulant prophylaxis, particularly early after the initial insult when bleeding progression is perceived to be highest. Because the administration of blood thinners could exacerbate bleeding in an enclosed space and result in the worsening of already poor neurologic function, these recommendations are reasonable.
On the other hand, the consequences of initiating VTE prophylaxis in this population may not be as devastating as one would think. In the general trauma population, thromboprophylaxis is the standard of care because of the astonishingly high incidence of deep venous thrombosis (DVT) development, which consistently exceeds 50% [2, 3] . Th e ability of DVT prophylaxis to achieve a substantial degree of risk reduction (approximately 50%), coupled with an overall low major bleeding rate (less than 2%) [4] , clearly demonstrates that the benefi ts of its use outweigh the risks of bleeding. Except for the diff erence in location of traumatic injury, those suff ering from traumatic ICHs are no diff erent than the general trauma population. To think that their risk of bleeding is
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Patients with traumatic brain injury and resultant intracranial hemorrhage (ICH) are at high risk for developing venous thromboembolism (VTE). The use of thromboprophylaxis is eff ective at decreasing the rate of VTE, but at the potential expense of an increased risk of ICH progression. Physicians must carefully consider both the benefi ts and risks of VTE prophylaxis before prescribing chemical anticoagulants to these patients. To help clarify this diffi cult choice, Scales and colleagues performed a decision analysis to determine whether the benefi ts of thromboprophylaxis outweigh the potential risk of worsening ICH. There is increasing evidence that bleeding risks are not as prominent as previously thought. Although the results were largely inconclusive, the present study has identifi ed areas for future research.
increased simply because of the location of bleeding does not seem biologically plausible. Additionally, prospective observational evidence has shown that progression of bleeding after traumatic head injuries is highest during the fi rst 24-hour period, even in the absence of thromboprophylaxis [5] . Despite initiation of DVT prophylaxis at 24 hours, the risk of bleeding does not signifi cantly increase (4%) unless a surgical procedure is required. Th us, in the appropriate patient suff ering from an ICH, the advantages of thromboprophylaxis outweigh potential disadvantages.
In the same vein, emerging data suggest that pharmaco logic prophylaxis with LMWH does not substantially increase anti-Xa levels when used for DVT prophylaxis, even for patients with severe renal impairment. Th e DIRECT (Dalteparin's Infl uence on the Renally Compromised: Anti-Xa) study [6] demonstrated that in 99% of patients with a creatinine clearance of less than 30 mL/ minute, trough anti-Xa levels were either undetectable (less than 0.10 IU/mL) or minimal (0.10 to 0.20 IU/mL). Additionally, no associa tion between major bleeding and anti-Xa levels was found. Th erefore, if LMWH does not accumulate even in the face of severe renal insuffi ciency, the likelihood that it will accumulate and precipitate bleeding seems low in a typical patient with traumatic ICH.
Growing evidence suggests that our current thromboprophylaxis regimens are relatively safe and possibly even suboptimal [7, 8] . Taking the risk-benefi t equation one step further, it is likely that the early administration of DVT prophylaxis in this patient population may be less hazardous than the alternative of full-dose anticoagulation or an inferior vena cava (IVC) fi lter when VTE actually develops. Th e potential long-term complications associated with an IVC fi lter, namely IVC thrombosis, migration of the fi lter [9] , and increased risk for DVT [10] , must be contemplated before its placement. Despite these considerations, the lack of concrete evidence from a randomized controlled trial leaves physicians skeptical about the safety of thromboprophylaxis in the setting of a traumatic ICH. Th is uncertainty is mirrored in the decision analysis by Scales and colleagues [1] , in which the estimated risk of ICH progression, even without exposure to anticoagulants, ranged widely from 0.001 to 0.990. Hence, at the very least, the fi ndings of this study illustrate that much research is still needed to clarify the appropriate timing, dose, and patient characteristics to safely administer VTE prophylaxis in this population. Furthermore, this study has identifi ed the need for a risk stratifi cation tool to select those patients who are at low risk for ICH progression and would be ideal candidates for DVT prophylaxis at 24 hours. In the meantime, while we await more information, it seems that the decision to administer thromboprophylaxis should be cautiously considered on an individual basis.
